We performed biological validation using blood specimens collected from biologically confirmed AD patients and matched healthy controls and found significant changes in the expression of three genes: FDX1, GLS, and PDK1, implicating that these genes could be used as easily available biomarkers for predicting AD occurrence. This evidence concerns the gene GLS and Alzheimer disease.